This is a comprehensive review covering scientific rationale, pre-clinical research, and clinical studies about a vast range of receptor targets (5-HT1A/1B, NMDA, AMPA, mGlu5, mGlu4, adenosine A2a). We also review a number of compounds that have reached the stage of clinical development, including compounds with complex pharmacological properties (such as amantadine, safinamide, zonisamide, pridopidine, mesdopetam). We conclude with some reflections on caveats and opportunities for present and future translational research in this area.
The journal has provided us with a personalized URL providing 50 days’ free access to our article. Anyone clicking on this link before May 06, 2022 will be taken directly to the final version of the article on ScienceDirect, which they are welcome to read or download. No sign up, registration or fees are required. https://authors.elsevier.com/a/1elxG6T90t3ZZ
Enjoy the reading!
Viewing 0 reply threads
You must be logged in to reply to this topic.
Cookies and Personal information
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.